A carregar...
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
Several concerns have been raised about the use of immunodepleting agents including alemtuzumab, cladribine and CD20-depleting antibodies in people with multiple sclerosis (pwMS) during the coronavirus disease (COVID) 2019 pandemic. As the end of the pandemic is not yet in sight, vaccination against...
Na minha lista:
| Publicado no: | Vaccines (Basel) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7911298/ https://ncbi.nlm.nih.gov/pubmed/33525459 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines9020099 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|